Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants (Q47993902)

7 February 2018

title

Safety and immunogenicity of two octavalent pneumococcal conjugate vaccines in American Indian infants (English)

1 reference

7 February 2018

3

Robert Weatherholtz

1 reference

7 February 2018

Mathuram Santosham

series ordinal

5

object named as

Mathuram Santosham

1 reference

7 February 2018

Angelia Eick

1

1 reference

7 February 2018

Janné Croll

series ordinal

2

1 reference

7 February 2018

Larry Croll

series ordinal

4

1 reference

7 February 2018

language of work or name

English

0 references

publication date

1 March 2004

1 reference

7 February 2018

published in

Vaccine

1 reference

7 February 2018

volume

22

1 reference

7 February 2018

issue

9-10

1 reference

7 February 2018

page(s)

1260-1264

1 reference

7 February 2018

High incidence rates of invasive pneumococcal disease in the White Mountain Apache population

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Pneumococcal Polysaccharide-Meningococcal Outer Membrane Protein Complex Conjugate Vaccine Is Immunogenic in Infants and Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Safety and immunogenicity of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously but in a separate syringe with diphtheria, tetanus and pertussis vaccines in Gambian infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Tolerability and immunogenicity of an 11-valent pneumococcal conjugate vaccine in adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Tolerability and immunogenicity of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: implications for development of a conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.026

10.1016/J.VACCINE.2003.09.026

7 January 2021

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018